Development and evaluation of a single domain antibody targeting folate receptor alpha for radioligand therapy
The therapeutic lead radiopharmaceutical [<sup>131</sup>I]I-GMIB-2BD42 showed fast pharmacokinetics with specific retention in hFRα + tumours. In addition, we report therapeutic efficacy with no signs of toxicity. In this study, we successfully designed a new drug for RLT, overcoming previous limitations, such as high kidney retention, which could aid in revitalising FRα-targeted radiotherapy.
Authors
- Hannelore Ceuppens (ORCID: https://orcid.org/0000-0003-0187-4204)
- Laurent Navarro (ORCID: https://orcid.org/0000-0002-3940-7954)
- Karine Breckpot (ORCID: https://orcid.org/0000-0003-4331-3480)
- Matthias D’Huyvetter (ORCID: https://orcid.org/0000-0002-6895-4260)
- Jo A. Van Ginderachter (ORCID: https://orcid.org/0000-0002-4442-7474)
- Francis Santens (ORCID: https://orcid.org/0000-0001-9521-9846)
- Jonatan Dewulf (ORCID: https://orcid.org/0000-0003-0697-7667)
- Nick Devoogdt (ORCID: https://orcid.org/0000-0001-9220-4833)
- Yana Dekempeneer (ORCID: https://orcid.org/0000-0002-9610-9064)
- Tony Lahoutte (ORCID: https://orcid.org/0000-0002-1773-8664)
- Sam Massa (ORCID: https://orcid.org/0000-0003-2896-3549)
Institutions
- Vrije Universiteit Brussel (BE)
- VIB-UGent Center for Inflammation Research (BE)
Publication Details
- Journal
- Journal of Nanobiotechnology
- Published
- 2024-12-19
- DOI
- https://doi.org/10.1186/s12951-024-03008-z
- Citations
- 8
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 2.26
Funders
- Région de Bruxelles-Capitale
- Innoviris
- Servier